Crohn's disease

By J. Torres, S. Mehandru, J. Colombel, L. Peyrin-Biroulet. The Lancet, 2017

1,297 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy (2019, background): “The introduction of anti-TNF antibodies has transformed the clinical outcome of IBD patients, but 20%–30% of iCD patients never respond to these drugs and continue to undergo uncontrolled bowel damage requiring surgical intervention within 10 years after the diagnosis (Torres et al., 2017).”
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020, neutral): “Overall 525 363 (69) 161 (31) 24 (5) 21 (4) 16 (3) 37 (7) Age, y 0–9 3 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 10–19 26 23 (88) 3 (12) 0 (0) 0 (0) 0 (0) 0 (0) 20–29 116 93 (80) 23 (20) 2 (2) 1 (1) 0 (0) 2 (2) 30–39 108 87 (81) 20 (19) 4 (4) 2 (2) 1 (1) 4 (4) 40–49 95 64 (67) 31 (33) 4 (4) 3 (3) 2 (2) ”